|
|
Lead and Cardiovascular Risk: Low Blood Levels Still Warrant Attention
|
|
By Julia Malkowski, ND, DC | October 27, 2026
|
Lead (Pb) is a well-recognized environmental toxicant, yet its connection to cardiovascular disease (CVD) risk is under recognized in clinical settings. A 2026 JAMA analysis estimated that Pb exposure accounted for 3.5 million deaths worldwide in 2023, making it the eighth leading risk factor for global mortality and the second leading environmental risk factor.
In a cohort of 14,289 US adults, those at the 90th percentile of blood Pb (6.7 µg/dL) had a 70% higher risk of cardiovascular death and a 108% higher risk of ischemic heart disease death than those at the 10th percentile (1.0 µg/dL). These associations persisted after adjustments for urinary cadmium (Cd) and other relevant covariates. The greatest incremental increase in risk occurs when moving from very low to moderately low blood Pb concentrations. The dose-response curve was steepest at the lower end of exposure, with no evidence of a safe threshold. Importantly, harm appears to occur well below levels long considered acceptable.
How Pb may damage the cardiovascular system
The mechanisms are increasingly well characterized, though their relative contributions in humans are still under study. Pb contributes to oxidative stress by binding sulfhydryl groups, depleting glutathione (GSH), and inhibiting delta-aminolevulinic acid dehydratase (ALAD), which allows ALA to accumulate and generate more reactive oxygen species (ROS). These ROS reduce nitric oxide bioavailability, while Pb also interferes with calcium signaling in vascular smooth muscle; together, these effects impair vasodilation and contribute to endothelial dysfunction and elevated blood pressure. Pb also promotes vascular inflammation by activating NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) in the vessel wall. The same oxidative stress converts ordinary low-density lipoprotein (LDL) into oxidized LDL, a downstream driver of plaque formation.
Where Pb exposure hides
A thorough exposure history is the most useful clinical tool. Consider asking about:
Home and environment
-
Drinking water (Pb service lines, older plumbing, solder, and fixtures)
-
Paint in older housing, and dust or soil from renovation or demolition
Occupation and hobbies
-
Construction or demolition, battery recycling or repair
-
Shooting ranges, ammunition handling, bullet casting, fishing sinkers
-
Glazes, ceramics, and stained glass
Consumer products
-
Antique or imported cookware, pottery, and crystal
-
Imported or unregulated products, including some cosmetics (such as kohl), spices, toys, and herbal or traditional remedies, as well as dietary supplements of any origin. Contamination depends on the manufacturer and sourcing, not the tradition.
Tobacco and vaping
-
Cigarettes (Pb and Cd)
-
Some vape devices and aerosols, where metals can leach from heating coils and other components into the e-liquid and aerosol; exposure varies by product and use
Testing considerations
Whole blood is the specimen of choice for current or recent Pb exposure. The blood lead level (BLL) is also what was used in the cohort data behind these risk estimates. Reference ranges vary by laboratory and agency, and a result within the stated normal range does not exclude past exposure or CVD risk.
Pb stored in bones can persist for decades and may be released during bone loss. Given the potential for bone loss with hormonal change, this is an important consideration for postmenopausal women. BLL mainly reflects recent exposure, a low result may underestimate cumulative burden.
When BLL is elevated, the priority is to identify and remediate the source of exposure. Markers of oxidative stress and cardiovascular risk may help guide individualized care, including RBC GSH, urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), and oxidized LDL. These biomarkers reflect oxidative stress broadly rather than Pb exposure specifically; therefore interpret them alongside the exposure history and clinical picture.
Supportive strategies
If Pb exposure exists currently and/or RBC GSH is low, consider supporting endogenous GSH synthesis by ensuring adequate protein and precursor amino acids, particularly cysteine and glycine, and by correcting relevant micronutrient insufficiencies. Because cysteine availability often limits GSH production, some clinicians use N-acetylcysteine (NAC) or undenatured whey protein as cysteine sources, or liposomal GSH when clinically appropriate.
Adequate iron, calcium, and zinc status is also worthwhile, because deficiencies can increase Pb absorption. Research on these approaches in Pb-exposed adults is still emerging, repletion of these nutrients should complement, not replace, identification and mitigation of the source.
Conclusion
Environmental Pb exposure should be considered a clinically relevant cardiovascular risk even when BLL falls within conventional reference limits. Pb has no biologically plausible safe threshold for cardiovascular outcomes and the risk may increase at relatively low levels. BLL primarily reflects recent exposure, therefore best practice is to combine laboratory findings with a careful exposure history. Identifying and removing the source remains the priority, while evaluation of oxidative stress, antioxidant status, and related clinical factors may help guide individualized supportive care.
|
References
-
GBD 2023 Lead Collaborators; Stanaway JD, Spearman S, DeCleene NK, et al. Lead-attributable cardiovascular disease burden: Global Burden of Disease Study 2023. JAMA. 2026;335(16):1418-1427. doi:10.1001/jama.2026.2197
-
Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW. Low-level lead exposure and mortality in US adults: a population-based cohort study. Lancet Public Health. 2018;3(4):e177-e184.
-
Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 µmol/L (10 µg/dL) and mortality among US adults. Circulation. 2006;114(13):1388-1394.
-
Lamas GA, Bhatnagar A, Jones MR, et al. Contaminant metals as cardiovascular risk factors: a scientific statement from the American Heart Association. J Am Heart Assoc. 2023;12(13):e029852.
|
|
|
|
|
|
|
|
The Aging Gut-Brain Axis: Dysbiosis, Intestinal Permeability, and Inflammaging in Clinical Practice
Presented by Julia Malkowski, ND, DC | November 4, 2026 at 12 PM Pacific
|
|
|
|
|
|
|
Gut microbial aging, intestinal barrier dysfunction, and chronic low-grade inflammation (inflammaging) are increasingly recognized as modifiable contributors to cognitive and functional decline. This session reviews how the gut microbiome changes with age, including loss of diversity and butyrate-producing taxa, and how these shifts weaken the mucosal barrier and increase zonulin and LPS translocation. It then follows the resulting inflammatory signal to the brain, where blood-brain barrier changes and neuroinflammation affect the hippocampus.
Attendees will learn which objective measures are available today (stool microbiome diversity and dysbiosis profiles, zonulin, hs-CRP) and how to incorporate these into practice. They will also learn how to apply evidence-based dietary, nutraceutical, and medication-review strategies in a rational sequence, with dosing limits and reassessment.
Learning Objectives:
-
Describe age-associated changes in gut microbiome composition and diversity, including loss of butyrate producers, and how they relate to biological age.
-
Explain how intestinal barrier dysfunction, zonulin, and LPS translocation contribute to inflammaging, neuroinflammation, and cognitive decline.
-
Interpret stool microbiome diversity and dysbiosis profiles, zonulin, and hs-CRP in a patient with cognitive or functional decline and recognize the limits of these tests.
-
Apply evidence-based dietary, nutraceutical, and medication-review strategies to restore microbial diversity and barrier integrity, including sequencing, dosing limits, and reassessment.
|
|
|
|
|
|
|
|
Laboratory, Endocrine, & Neurotransmitter Symposium
|
|
|
|
|
|
|
Join us in Costa Mesa on February 26 and 27, 2027 for LENS, a weekend of education built on current research and real clinical cases. Seasoned practitioners will explore the connections among sex hormones, the HPA axis, neurotransmitters, the gut microbiome, and mitochondrial health, with sessions on menopause and gut health, neuroinflammation, NAD⁺ testing, testosterone therapy, methylation, and urinary hormone metabolites.
Early bird pricing is available through February 1, 2027: $499 for one ticket, or $399 each when you purchase two or more. LENS is an in person event only, with all sessions held live in Costa Mesa and no live stream offered.
Registration Includes:
- 14.5 AMA PRA Category 1 Credit(s) and AAPA Category 1 CME credits
- Recordings of all presentations
- Lunch, snacks, and an evening reception with raffle prizes
- Live Q&A panels and networking with colleagues, speakers, and exhibitors
|
|
|
|
|
|
|
Disclaimer: All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.
|
|
|
|
|
|
|
800.323.2784 (US and Canada)
+1.630.377.8139 (Global)
|
|
|
|
|
|
